CLINICAL POLICY: Dupixent (dupilumab) - Insurance Medical Policy
EFFECTIVE DATE: 01/15/2024
LAST REVIEW DATE: 11/01/2024
POLICY NUMBER: RX-2024-BIO-017

I. COVERED INDICATIONS
Dupixent is covered for the treatment of:
- Moderate-to-severe atopic dermatitis (eczema)
- Moderate-to-severe asthma with eosinophilic phenotype or oral corticosteroid dependence
- Chronic rhinosinusitis with nasal polyposis (CRSwNP)
- Eosinophilic esophagitis (EoE)
- Prurigo nodularis

II. GENERAL COVERAGE CRITERIA
Coverage for Dupixent requires meeting ALL general criteria plus indication-specific criteria:

1. Age Requirements:
   a. Atopic dermatitis: ≥ 6 months of age
   b. Asthma: ≥ 6 years of age (see clinical guidelines for phenotype criteria)
   c. CRSwNP: ≥ 18 years of age
   d. EoE: ≥ 12 years of age (weight ≥ 40 kg required)
   e. Prurigo nodularis: ≥ 18 years of age

2. Prescriber Requirement: Must be prescribed by or in consultation with:
   a. Dermatologist (for AD, PN)
   b. Allergist/Immunologist (for asthma, AD, EoE)
   c. Pulmonologist (for asthma)
   d. Otolaryngologist (for CRSwNP)
   e. Gastroenterologist (for EoE)

3. Documentation Requirements:
   a. Baseline disease severity scores as per specialty society guidelines
   b. Complete medication history including dates and doses
   c. For pediatric patients: growth charts and weight documentation

III. INDICATION-SPECIFIC CRITERIA

A. ATOPIC DERMATITIS
1. Disease severity documented by EASI score ≥ 16 OR IGA ≥ 3 (see clinical guidelines for scoring details)
2. Body surface area involvement ≥ 10%
3. Failed topical therapy as outlined in Section IV.A

B. ASTHMA
1. Confirmed eosinophilic phenotype (see clinical guidelines for specific eosinophil thresholds by age)
2. ≥ 2 exacerbations in past 12 months requiring systemic corticosteroids
3. Current therapy must include high-dose ICS/LABA (refer to GINA guidelines for dosing)

C. CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
1. Bilateral nasal polyps confirmed by endoscopy (NPS ≥ 5)
2. Sino-Nasal Outcome Test (SNOT-22) score (threshold per clinical guidelines)
3. Failed medical management per Section IV.C

D. EOSINOPHILIC ESOPHAGITIS
1. Histologic confirmation: peak eosinophil count per clinical guidelines
2. Symptomatic disease despite PPI therapy
3. For patients < 18 years: weight-based dosing per manufacturer guidelines

E. PRURIGO NODULARIS
1. ≥ 20 nodules present
2. Pruritus NRS ≥ 7 (see clinical guidelines for assessment method)
3. Failed therapies per Section IV.E

IV. REQUIRED PRIOR THERAPIES
[Note: Specific duration requirements and combinations per accompanying clinical guidelines]

A. Atopic Dermatitis:
   - High-potency topical corticosteroids
   - Topical calcineurin inhibitors
   - For moderate-severe cases: phototherapy or systemic immunosuppressant

B. Asthma:
   - Maximized inhaler therapy per GINA step 4-5
   - Trial of additional controller per clinical guidelines

C. CRSwNP:
   - Intranasal corticosteroids (specific duration per guidelines)
   - Systemic corticosteroids (number of courses per guidelines)
   - Consideration of surgical intervention

D. EoE:
   - High-dose PPI therapy (dosing per weight/age in guidelines)
   - Dietary elimination if applicable
   - Topical corticosteroids

E. Prurigo Nodularis:
   - Super-potent topical corticosteroids
   - At least ONE systemic therapy from clinical guidelines list

V. DURATION OF APPROVAL
Initial approval: 6 months (all indications)
Renewal: 12 months if meeting continuation criteria

VI. CONTINUATION CRITERIA
See accompanying clinical practice guidelines for specific response criteria by indication.
General requirement: No new safety concerns or contraindications